Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Treatment Resistant Depression Clinical Trials Market Overview
A total of 500 Treatment Resistant Depression clinical trials were conducted as of October 2022. The Treatment Resistant Depression clinical trial report provides a comprehensive understanding of the Treatment Resistant Depression clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · United States
· Canada · United Kingdom · Germany · Belgium · Australia · Brazil · France · China · Japan |
Key Sponsor Types | · Institution
· Company · Government |
Leading Sponsors | · Johnson & Johnson
· Compass Pathways Plc · F. Hoffmann-La Roche Ltd · AstraZeneca Plc · Bristol-Myers Squibb Co Plc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Treatment Resistant Depression Clinical Trials Segmentation by Regions and Countries
The key regions in the Treatment Resistant Depression clinical trials market are the Asia-Pacific, North America, Europe, Middle East & Africa, and South & Central America.
In the country-wise analysis, the US had the highest number of Treatment Resistant Depression clinical trials as of October 2022. France had the highest average patient enrollment of treatment resistant depression clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Canada had the highest proportion of Treatment Resistant Depression to Central Nervous System clinical trials as of October 2022.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil has the highest proportion of Treatment Resistant Depression to Central Nervous System clinical trials as of October 2022.
Treatment Resistant Depression Clinical Trials Analysis by Regions, 2022 (%)
Buy the Full Report for More Regional Insights into the Treatment Resistant Depression Clinical Trials Market, Download a Free Sample Report
Treatment Resistant Depression Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Treatment Resistant Depression clinical trials market are institution, company, and the government. As of October 2022, 54% of Treatment Resistant Depression clinical trials were conducted by institution sponsor type.
Treatment Resistant Depression Clinical Trials Market Analysis by Sponsor Types, 2022 (%)
Buy the Full Report for More Sponsor Type Insights into the Treatment Resistant Depression Clinical Trials Market, Download a Free Report Sample
Treatment Resistant Depression Clinical Trials Market - Competitive Landscape
In 2022, Johnson & Johnson conducted the highest number of Treatment Resistant Depression clinical trials.
A few of the leading sponsors in the Treatment Resistant Depression clinical trials market are:
- Johnson & Johnson
- Compass Pathways Plc
- Hoffmann-La Roche Ltd
- AstraZeneca Plc
- Bristol-Myers Squibb Co
Treatment Resistant Depression Clinical Trials Market Analysis by Sponsors 2022 (%)
Buy the Full Report for More Leading Sponsors Insights into the Treatment Resistant Depression Clinical Trials Market, Download a Free Sample Report
Segments Covered in the Report
Treatment Resistant Depression Clinical Trials Region Outlook (2022)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Treatment Resistant Depression Clinical Trials Country Outlook (2022)
- United States
- Canada
- United Kingdom
- Germany
- Belgium
- Australia
- Brazil
- France
- China
- Japan
Treatment Resistant Depression Clinical Trials Sponsor Type Outlook (2022)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for the unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Compass Pathways Plc
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Axsome Therapeutics Inc
Otsuka Holdings Co Ltd
Eli Lilly and Co
The Lundbeck Foundation
Alkermes Plc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the Treatment Resistant Depression clinical trials market?
The key regions in the Treatment Resistant Depression clinical trials market are the Middle East & Africa, Asia-Pacific, Europe, North America, and South & Central America.
-
What are the key countries in the Treatment Resistant Depression clinical trials market?
The key countries in the Treatment Resistant Depression clinical trials market are the US, Canada, the UK, Germany, Belgium, Australia, Brazil, France, China, and Japan.
-
What are the key sponsor types in the Treatment Resistant Depression clinical trials market?
The key sponsor types in the Treatment Resistant Depression clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Treatment Resistant Depression clinical trials market?
The leading sponsors in the Treatment Resistant Depression clinical trials market are Johnson & Johnson, Compass Pathways Plc, F. Hoffmann-La Roche Ltd, AstraZeneca Plc, Bristol-Myers Squibb Co, Axsome Therapeutics Inc, Otsuka Holdings Co Ltd, Eli Lilly and Co, The Lundbeck Foundation, and Alkermes Plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.